Molina Healthcare Set for Q3 Earnings: Revenue Gains, But Profit Pains

Molina Healthcare (MOH) is projected to report a significant 33.9% year-over-year decline in Q3 2025 earnings per share to $3.97, despite an anticipated 5.4% revenue increase to $10.9 billion. This expected profit contraction is primarily driven by higher medical care costs, increased general and administrative expenses, and a 15.3% drop in investment income, alongside rising Medical Care Ratios. With a Zacks Rank #4 (Sell) and 0.00% Earnings ESP, the company faces an uncertain earnings beat, reflecting profitability challenges despite membership growth in its Medicare and Marketplace segments.

Analysis

Molina Healthcare (MOH) is anticipated to report a substantial 33.9% year-over-year decline in Q3 2025 EPS to $3.97, despite projected revenue growth of 5.4% to $10.9 billion. This trend extends to the full year, with 2025 EPS expected to fall 16.7% to $18.87, while revenues are forecast to rise 9.6% to $44.54 billion. The upcoming Q3 report on October 22nd will be critical in confirming these diverging trends.
The primary drivers of this profitability pressure are escalating costs and reduced investment income. The Medical Care Ratio (MCR) is expected to worsen, with Marketplace MCR rising to 84.67% from 73% and total MCR increasing to 90.32% from 89.20% year-over-year. Additionally, total operating expenses are projected to climb over 6% due to higher medical care and G&A costs, compounded by an estimated 15.3% decline in investment income.
While MOH is experiencing robust membership growth in Medicare (+6.5%) and Marketplace (+60.8%), partially offset by a 2.8% decrease in Medicaid, these gains are not translating into improved bottom-line performance. The Zacks model does not predict an earnings beat, with a 0.00% Earnings ESP and a Zacks Rank #4 (Sell), underscoring a cautious outlook from analysts regarding the company's near-term earnings potential.

Key Decisions for Investors

• Investors should exercise caution given the projected significant EPS decline and Zacks Rank #4 (Sell) for Molina Healthcare.
• Monitor the Q3 earnings report closely for actual Medical Care Ratio trends and management's commentary on cost containment strategies.
• Evaluate the sustainability of membership growth across segments against the backdrop of persistent profitability challenges and declining investment income.